Recovery Kentucky was created to help Kentuckians recover from substance abuse, which often leads to chronic homelessness. Two hundred and eighty clients from 17 established Recovery Kentucky programs participated in the Recovery Center Outcome Study between July 2016 and June 2017 and a 12-month follow-up survey between July 2017 and June 2018. The average number of days after program exit the follow-up interviews were conducted was 210, which is about 6.9 months.

**Significant reductions in past-6-month Substance Use and Mental Health Problems**

- **Reported any illegal drug use***
  - At intake: 92%
  - At follow-up: 10%

- **Reported opioid use***
  - At intake: 68%
  - At follow-up: 4%

- **Reported heroin use***
  - At intake: 43%
  - At follow-up: 4%

- **Reported stimulant use***
  - At intake: 50%
  - At follow-up: 3%

- **MET study criteria for depression***
  - At intake: 72%
  - At follow-up: 13%

- **MET study criteria for anxiety***
  - At intake: 76%
  - At follow-up: 16%

- **MET study criteria for comorbid depression and anxiety***
  - At intake: 64%
  - At follow-up: 8%

- **Reported suicidal ideation and/or attempts***
  - At intake: 36%
  - At follow-up: 3%

**Significant reductions in past-6-month Economic Indicators**

- **Currently homeless***
  - At intake: 38%
  - At follow-up: 5%

- **Reported difficulty meeting basic living needs***
  - At intake: 47%
  - At follow-up: 17%

- **Reported difficulty meeting health care needs***
  - At intake: 26%
  - At follow-up: 7%

- **Reported attending mutual help recovery meeting in the past 30 days***
  - At intake: 38%
  - At follow-up: 82%

- **Estimated cost-savings for taxpayers***
  - Using national estimates of the cost of substance abuse and applying them to clients’ substance use before and after program participation, there was an estimated $2.56 return in avoided costs for every dollar invested in providing recovery services.

1 Misuse of opioids other than heroin, including prescription opiates, methadone, and buprenorphine.
2 Amphetamine, methamphetamine, Ecstasy, Ritalin.